Please try another search
For the fiscal year ended 31 December 2017, Alzheon Inc revenues was not reported. Net loss before extraordinary items decreased 22% to $11.3M. Lower net loss reflects Research and development decrease of 60% to $1.7M (expense), Interest expense, net decrease of 54% to $353K (expense), General and administrative decrease of 11% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.75.
Period Ending: | Dec 31, 2017 | Dec 31, 2016 |
---|---|---|
Total Revenue | 0 | 0 |
Gross Profit | ||
Operating Income | -5.1 | -6.93 |
Net Income | -5.45 | -7.7 |
Period Ending: | Dec 31, 2017 | Dec 31, 2016 |
---|---|---|
Total Assets | 7.39 | 2.86 |
Total Liabilities | 1.27 | 10.81 |
Total Equity | 6.12 | -7.95 |
Period Ending: | Dec 31, 2017 | Dec 31, 2016 |
---|---|---|
Period Length: | 12 Months | 12 Months |
Cash From Operating Activities | -3.34 | -7.56 |
Cash From Investing Activities | -0.01 | -0.01 |
Cash From Financing Activities | 6.99 | 3.01 |
Net Change in Cash | 3.64 | -4.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review